Archive for the ‘Testing’ Category

The Pfizer Job

Before reading the following unbelievably detailed analysis that took the author and his team over 3 years to complete, it’s important to note that ‘the powers that be’ aren’t getting the memo. Bill Gates recently had two meetings at the White House with President Trump and not only wants to inject cows and start putting scary additives into their food to supposedly reduce methane, but he’s funding a new micro-needle patch implant that installs both mRNA and quantum-dot markings into the body. Dr. Jessica Rose has broken it all down here.  Suffice it to say that it’s even worse than the mRNA shots.  In Rose’s words:

[It] involves taking the N1-modified mRNA-LNP technology (Pfizer/Moderna idea) to the next level of crazy, in my opinion.

And, Moderna has just unveiled a new mRNA shot called ‘mNEXSPIKE’ which translated in Latin means ‘violent death, or ‘death spear.’  You seriously can’t make this up.

Does anyone else out there get the distinct impression they want us dead?

https://www.arkmedic.info/p/the-pfizer-job?

The Pfizer Job

How Pfizer carried out the biggest pharma trial heist ever – and the regulators swallowed it hook, line and sinker.

Dr Ah Kahn Syed
Oct 12, 2025
Remember this?

Article Excerpts:

“Pfizer’s vaccine is more than 90% effective”.

Headlines repeated around the world and more importantly by the regulators FDA, TGA, EMA and MHRA.

Just to reiterate – this was about COVID infection. No claims on severity, hospitalisation or death were made by Pfizer.

Given that most of the vaccinated population actually “got COVID” – many of them multiple times, that sounds impossible, right?

That’s because it was.

Yet the trial itself showed 95% reduction in the risk of infection and was published in the infamous New England Journal of Medicine (the same journal that published the fraudulent Surgisphere study) on the 10th December 2020.

….we are going to show that the whole study was a sham and that there never was a benefit – at all, never mind “95% reduction in infection.”  (See link for article)

________________

**Comment**

I’m eternally grateful that researchers and doctors are now onto the prolific research fraud that has been taking place.  Of course, this fraud has been going on in Lymeland for over 40 years, but now it’s on display for the entire world to see.  Yet another silver lining that came out of COVID mania.

SUMMARY:

  • One of the main Pfizer hustles was mandating all PCR swabs for the trial be sent to their own lab in New York as part of the case definition.  Which means that Pfizer decided whether a swab was positive or negative – the only test that mattered.
  • We only know this is due to a FOIA by attorney Aaron Siri.  Pfizer and the FDA tried to withhold this intel for 75 years.
  • Another hustle concerns dates.  The cut off for the trial was Nov. 14, 2020.  The VRBPAC meeting was on Dec. 10, 2020, the same day the trial was published.  The VRBPAC assessment document for the Pfizer submission was written on Dec. 7, 2020, just two weeks after the submission – having to assess 44,000 participants.  The approval was made on the basis of 47 days of follow-up for most patients, but was also made in ONE DAY, because of the VRBPAC meeting on Dec. 20, 2020 – with EUA declared on Dec. 11, 2020.  Certainly a miracle.
  • The dates demonstrate that all of this was impossible, which implies it was a pre-agreed approval based upon Pfizer showing data that there were less infections in the ‘vaccinated’ group based on a test they controlled – not on clinical symptoms.
  • Evidently, Doran Fink of the FDA presented in the VRBPAC meeting despite having no clinical data and no experience in handling large data sets.  Unblinding in the trial was not allowed to happen until after Nov. 14, 2020, yet somehow Pfizer knew what was in which arm before that date.  Interestingly, Fink was then given a job at Moderna and now is at GSK, demonstrating clearly the revolving door between the FDA and Big Pharma.
  • Even more miraculously Pfizer, the WEF, and mainstream media already knew by the 9th of November that the ‘vaccine’ had ‘worked’ despite the fact the data cut off was Nov. 14.
  • Susan K Wollersheim’s ability to give the statistical presentation for VRBPAC on a 44,000 participant clinical trial is legendary as she has never published a clinical research study7.  
  • There is no way Fink and Wollersheim did the analysis as they don’t have the skill set and they didn’t have the time necessary to do it.
  • The good doctor who authored this article, Dr Ah Kahn Syed, states that it took him and a handful of people with the skillset required 3 years to sift through over 2 MILLION pages of FDA documents to just write this article.
  • Moderna achieved a similar EUA approval only 7 days later due to a similar hustle.
  • The third hustle: they stopped accumulating cases (in the “vaccinated group” only) for a specified time period in order to make the cut.
  • A tactic they probably used, since they solely controlled testing, was to change the Cycle threshold on the machine recording the tests.  A Ct of over 40 will pick up a bunch of false positives and a low Ct of less than 16 will only pick up real cases with a high viral load.  They didn’t know the ‘sweet spot,’ so they had to change Ct as they went along.  The field that should have recorded the Ct on the machine is conveniently missing.
  • Pfizer knew which tests were from the ‘vaccinated’ or the placebo group because they had the blood tests from every person in the study at their lab. Castruita showed in 2023 that even after 4 weeks there was enough circulating RNA (or DNA) from the COVID-19 vaccines to be able to perform genomic sequencing13.  While unlocking the database would create audit flags, they could easily identify who got what without raising audit flags, so they could then adjust the Ct up or down depending upon the number of positive tests they needed.
  • The author proves that if you correct for the fact that, if you’re vaccinated, you have 2.3x less chance of showing N-antibody on a test, the infection rate of the ‘vaccinated’ and of the placebo group is identical.  There was no 95% reduction in infection in the ‘vaccinated’ group at all.  It was a scam.
  • The author also shows from The FDA’s review that there were over 1100 more fevers and over 2000 more reports of chills in the ‘vaccinated’ group.

Sadly, all of this should have been done before ‘Operation Warp-speed,’ but let this be a solid reminder to not take ANYTHING until you are fully convinced it truly works and is safe.  In short, do not believe anything the medical machine for profit says.  Before you take anything they recommend, wait until independent research has been done.

There are probably many, many people who are now living with a lot of regret.

Category:

Activism, Testing, vaccines, Viruses

Eczema & Hair Loss: Finally Diagnosed With Lyme Disease

https://nypost.com/2025/10/10/health/danielle-jonas-diagnosed-with-lyme-disease-after-experiencing-traumatic-symptom/

Kevin Jonas’ wife Danielle Jonas was diagnosed with Lyme disease after experiencing this ‘very traumatic’ symptom

By Reda Wigle
Published Oct. 10, 2025

Danielle Jonas, wife of Kevin Jonas, is revealing the stressful symptoms that led to her recent diagnosis of Lyme disease.

Jonas, 39, sought treatment when she noticed that she was shedding more hair than usual.

“They tried to tell me it was anxiety. Finally, I had a biopsy that showed I actually had Lyme disease,” Jonas said in an interview with Parents published on Thursday….

Years before the Lyme diagnosis, Jonas had experienced symptoms of eczema. They seemed to worsen during this new health battle.  (See link for article)

______________

**Comment**

Jonas’ children also suffer from eczema and other skin issues.

For more:

Category:

Activism, Lyme, Testing

Two Tests Outperform Current Tests for Detecting Early Lyme Disease

https://www.bayarealyme.org/blog/journal-of-clinical-microbiology-studies-demonstrate-two-investigational-diagnostics-outperform-current-tests-in-detecting-early-lyme-disease/

Journal of Clinical Microbiology Studies Demonstrate Two Investigational Diagnostics Outperform Current Tests in Detecting Early Lyme Disease

Journal of Clinical Microbiology Studies Demonstrate Two Investigational Diagnostics Outperform Current Tests in Detecting Early Lyme Disease
 | Diagnostics, NewsBy Bay Area Lyme Foundation

FOR IMMEDIATE RELEASE

Journal of Clinical Microbiology Studies Demonstrate Two Investigational Diagnostics Outperform Current Tests in Detecting Early Lyme Disease

Studies utilize Bay Area Lyme Foundation’s Lyme Disease Biobank samples to point to the promise of single-tier diagnostics to potentially transform early detection

PORTOLA VALLEY, Calif., October 9, 2025 — Bay Area Lyme Foundation, the leading nonprofit funder of Lyme disease research in the US, today announced results from two independent studies published in Journal of Clinical Microbiology, conducted by researchers at Tufts University School of Medicine, and Kephera Diagnostics, respectively, demonstrating the potential of novel investigational single-tier Lyme disease tests to improve accuracy in the earliest stages of infection. Each study uses well-characterized samples from Bay Area Lyme Foundation’s Lyme Disease Biobank and demonstrated unprecedented accuracy, far exceeding the current CDC-recommended Lyme disease two-tier test, which can miss up to 70% of early-stage cases as well as later-stage cases.

“The CDC’s standard two-tier Lyme diagnostic misses the majority of early cases, delaying treatment and increasing the risk of developing persistent, debilitating symptoms for patients. The two novel single-tier assays—while not yet FDA-cleared for clinical use—point to a future where Lyme disease can be diagnosed quickly, accurately, and with a single test,” Liz Horn, PhD, MBI, a coauthor on both studies, and Principal Investigator of Lyme Disease Biobank, a Bay Area Lyme Foundation program that provides much-needed samples to approved researchers working to better understand tick-borne diseases and develop improved diagnostic tests and therapeutics. “These single tier tests, like InBios Lyme Detect™ and Kephera’s Hybrid Lyme ELISA could mark a turning point for Lyme diagnostics, giving physicians and patients more accurate tools that are urgently needed.”

The first study, evaluating the InBios Lyme Detect™ Multiplex ELISA, was conducted by Pete Gwynne, PhD, a 2022 Bay Area Lyme Emerging Leader Award (ELA) winner, and colleagues at Tufts University School of Medicine. Using samples from the Lyme Disease Biobank, this new diagnostic correctly identified all two-tier positive samples evaluated in the study, while also detecting 21 of 79 clinically diagnosed patients who were missed by following the current CDC guidance for testing using FDA-cleared standard two-tier tests (STTT) and had erythema migrans (EM) skin lesions. Importantly, the InBios test maintained >99% specificity, with only one false positive across more than 200 control and lookalike disease samples and was shown to be highly reproducible.

“Improving diagnostics for early Lyme detection is critical to reducing missed cases and enabling patient access to treatment when it is most effective, helping prevent disease progression,” said Pete Gwynne, PhD, Research Assistant Professor of Molecular Biology and Microbiology at Tufts University School of Medicine. “The use of Lyme Disease Biobank samples to validate this research highlights the important role biorepositories can play in innovative science.”

InBios’ microarray-based assay is designed to capture reactivity against a set of 10 different Borrelia burgdorferi antigens simultaneously including VlsE and multiple OspC variants, and it uses machine learning to analyze results, identifying complex patterns.

“The Lyme Detect Multiplex ELISA offers a significant improvement in early Lyme detection while simultaneously providing important independent IgG and IgM antibody reactivity against a broad panel of targets,” said James Needham, PhD, Director of New Product Development at InBios International.

Another recent independent study published in the Journal of Clinical Microbiology in August found Kephera Diagnostics’ Hybrid Lyme ELISA demonstrated 94% sensitivity in patients with EM skin lesions, compared to just 64% for STTT and 76% for modified two-tier testing (MTTT). The Hybrid Lyme ELISA likewise outperformed both two-tier methods in detection of EM patients within the first week after onset of symptoms. This single-tier test achieved equivalent specificity to both STTT and MTTT, based on a unique approach that requires antibodies to bind both the Borrelia C6 peptide and the VlsE protein. The test is now in clinical trials to support an FDA submission.

“Our Hybrid Lyme ELISA demonstrates that it’s possible to achieve both high sensitivity and high specificity in a single-tier format, even in the earliest stages of Lyme disease,” said Andrew Levin, PhD, Chief Executive and Scientific Officer of Kephera Diagnostics, who led this study using samples from the Lyme Disease Biobank, the CDC, and New York Medical College. “Access to well-characterized samples was essential to validating this approach and moving the field closer to a reliable, first-line diagnostic for Lyme.”

About Lyme disease
The most common vector-borne infectious disease in the US, Lyme disease is a potentially disabling infection caused by bacteria transmitted through the bite of an infected tick to people and pets, and can be potentially passed from a pregnant mother to her unborn baby. If caught early, most cases of Lyme disease can be effectively treated, but it is commonly misdiagnosed due to lack of awareness and inaccurate diagnostic tests. There are more than 620,000 new cases of Lyme disease each year, according to Bay Area Lyme Foundation estimates. As a result of the difficulty in diagnosing and treating Lyme disease, up to two million Americans may be suffering from the impact of its debilitating long-term symptoms and complications, according to Bay Area Lyme Foundation estimates.

About Lyme Disease Biobank
Lyme Disease Biobank (LDB), a program of Bay Area Lyme Foundation, is a non-profit organization working to accelerate research of Lyme disease and other tick-borne infections. With a collection of biological specimens from more than 1,250 participants, including blood, serum, plasma, urine and tissue, LDB provides much-needed samples to approved researchers working to better understand tick-borne diseases and develop improved diagnostic tests and therapeutics. Blood and urine samples are collected from the Northeast, Upper Midwest and West Coast areas of the US, and tissue samples are collected throughout the country. Researchers interested in obtaining samples should visit www.lymebiobank.org or contact info@lymebiobank.org.

About Bay Area Lyme Foundation
Bay Area Lyme Foundation, a national organization committed to making Lyme disease easy to diagnose and simple to cure, is the leading public charity sponsor of innovative Lyme disease research in the US. A 501c3 organization based in Silicon Valley, Bay Area Lyme Foundation collaborates with world-class scientists and institutions to accelerate medical breakthroughs for Lyme disease. It is also dedicated to providing reliable, fact-based information so that prevention and the importance of early treatment are common knowledge. Historically, a pivotal donation from the LaureL STEM fund covered all overhead costs through 2024. In 2023, a Bay Area Lyme Endowment was formed, which allows for 100% of all donor contributions to the Bay Area Lyme Foundation to go directly to research and prevention programs in perpetuity. For more information about Lyme disease or to get involved, visit www.bayarealyme.org or call us at 650-530-2439.

About InBios
Since 1996, InBios has been a leader in the development of diagnostic tests for emerging infectious diseases and biothreats. Products are designed for superior performance, efficiency and value. These include several FDA market authorized and CE marked assays for arboviruses, parasitic infections, biothreats, and more. InBios continues to anticipate and serve the growing global public health demand. Products in the pipeline include next generation platforms for Chagas, dengue, tick-borne and respiratory diseases. For more information, visit www.inbios.com.

About Kephera Diagnostics
Kephera Diagnostics is a young and growing company that is addressing the public health challenges of global infectious diseases using new assay technologies.  We also operate a CLIA-certified and CAP-accredited diagnostic laboratory delivering excellence in specialized diagnostics. We focus on diagnostic solutions for diseases where there are significant gaps in addressing patient needs, particularly in underserved areas of healthcare including infectious diseases and women’s health. Our mission is to promote more effective and affordable medical treatment through faster diagnosis. We collaborate with a global community of researchers and clinicians to develop and translate new technologies into accessible products for clinical diagnostics and research applications.

# # #

Media Contact:
Tara DiMilia
Phone: 908-369-7168
Tara.DiMilia@tmstrat.com

______________

**Comment**

Not sure why Bay Area Foundation is stating that congenital Lyme can potentially happen.  It can happen – period and 33 years of of documentation proves it.

Interesting to note:

“study co-author Gary P. Wormser, MD, New York Medical College said, “This test [Kephera Diagnostics’s Hybrid Lyme ELISA] could potentially change the standard of clinical practice, allowing clinicians to diagnose all manifestations of Lyme disease with a time-saving one-step antibody test.”

Why the Lyme/MSIDS community is still working with Gary Wormser is beyond me.  His track record is clear.

Having a quicker, more accurate test for early Lyme is important, but so is an accurate test for the thousands upon thousands who are chronically infected.

It will be interesting to see what ‘the powers that be’ do with all these new tests coming out. The concerted effort against direct testing or any test that is deemed competition to FDA/CDC testing has been decades in the making.

Category:

Activism, Lyme, research, Testing, Uncategorized

Inside IGeneX’s New Lyme Test

http://  Approx. 55 Min

Inside IGeneX’s Game-Changing Lyme Test

Dr. Jyotsna Shah

Oct 7, 2025
 
Dr. Jyotsna Shah is an immunologist and molecular biologist with over 40 years of experience in diagnostic tools for tick-borne diseases. She holds a Ph.D. in diagnostic immunology from the University of Nairobi and conducted postdoctoral work at Harvard University.
 
Shah joined IGeneX in 1997, becoming Laboratory Director in 2003 and now serving as President and CEO.
_____________
 
**Comment**

Like so many other pioneers who expose inconvenient truths about Lyme, the Michigan State Attorney’s Office told Dr. Lida Mattman to stop testing for Lyme using her gold standard direct culture technique.  She also successfully duplicated the results of the Bowen Q-RiBb test, which provided a preliminary report of the findings within 24 hours of receiving the specimen. The final report included digital photographs of the finding, which was useful in evaluating treatment by comparing pre and post serial dilution results.

Direct testing for Lyme has been attacked for over 20 years.  The CDC has persecuted any test they don’t have control over and get kick backs from.

Mattman was subsequently threatened with time in jail or a fine of 5,000 dollars a day.  State police arrived at her lab with handcuffs and tried to find evidence that she was still testing but they didn’t find what they were looking for. She was forced to stop her valuable work and leave her lab.

The continued adherence to worthless 2-tier CDC testing is on purpose.  They don’t want an accurate test – they’ve had two already and buried them!

I question the use of PCR for diagnosing anything.  Just look at the COVID fiasco due to faulty testing.  Time will tell on this new IGeneX test.

For more:

Despite having nearly every symptom and being ER bound, neither my husband nor I managed to test positively on the CDC’s 2-tiered testing which sets arbitrary limits and omits the most specific band that is sometimes the only marker for those with late-stage Lyme due to decision made in Dearborn, Michigan decades ago.

The most divisive part of the two-step diagnostic standard – now called the Dearborn criteria – was elimination from the Western blot of two Bb proteins, outer surface protein A (OspA), from which LYMErix was made, and outer surface protein B (OspB), the intended component of next-generation vaccines.  Source

 

 

 
 

Category:

Lyme, research, Testing, Uncategorized

Why Millions Are Suffering in Silence: A Global Health Crisis

https://lymecare.org/posts/globalhealthcrisis/

Why Millions Are Suffering in Silence: A Global Health Crisis

The Silent Pandemic: Misdiagnosis and Urgent Lyme Disease Awareness
The Silent Pandemic: Misdiagnosis and Urgent Lyme Disease Awareness

Imagine waking up every morning feeling slightly off—just a bit out of sorts. Sometimes there’s a headache, other times an overwhelming sense of tiredness that even a strong cup of coffee can’t shake. You chalk it up to stress, the inevitable wear and tear of a busy life. But as the months pass, your symptoms worsen. By mid-morning, your energy is drained, and strange, fleeting moments of dizziness and confusion disrupt your routine. You tell yourself it’s nothing serious, probably just burnout. Until, one day, the fog in your mind becomes so dense that you can’t recall simple tasks or details you’ve known your entire life.

Doctors Tell You: It’s All in Your Head

When you finally turn to doctors for help, they dismiss your concerns. They tell you it’s all in your head—that you’re stressed, depressed, or simply overworked. You’re prescribed herbal supplements like valerian and ginkgo biloba, and receive a laundry list of vague diagnoses: fibromyalgia, chronic fatigue syndrome, multiple sclerosis, or worse, psychiatric disorders. The medications don’t help, the tests come back inconclusive, and years pass as you’re left searching for answers. Bit by bit, you start to lose touch with your loved ones, as friends and family struggle to understand the invisible illness consuming your life.

The Inadequate Excuse of Covid

Maybe you had Covid a few months or a year ago, and now doctors insist your lingering symptoms are due to Long Covid. But you know plenty of people who had the virus and are perfectly healthy today, long past their infection. The Covid pandemic, while devastating, has also become a convenient excuse to mask a deeper, more sinister truth.

The Real Cause: A Hidden Infection

All the while, the real culprit—a stealthy bacterial infection called Borrelia—is quietly ravaging your body, undetected by the very healthcare system that should be safeguarding you. And you’re not alone. Millions of people worldwide are suffering in silence, unaware that Borrelia is behind their mysterious ailments.

Despite the severity of the infection, few around you have even heard of Borrelia or understand the damage it can cause. Even the most expensive doctors fail to recognize its effects. (See link for article)

_______________

**Comment**

Part of the reason I don’t write more articles is because I spend a great deal of time correcting articles written by others.  It amazes me to no end how the accepted narrative of Lyme/MSIDS can still remain so pervasive after 40 years.

That said, this well written article only needs an update on some new research.  Since no date is included about when the article was written, but mentioned COVID, we can assume it was written sometime in the past 5 years.

Just this year (2025), a study showed that there is no evidence mosquitoes can transmit Bb, as the bacteria can not survive in their guts long enough to reach their salivary glands to be able to transmit the disease.  A few findings:

  • Mosquitoes exhibited low efficiency in acquiring Borrelia from infected hosts.
  • Spirochetes artificially introduced through ex vivo blood meals were rapidly eliminated during digestion, primarily due to trypsin activity.
  • Inhibition of trypsin prolonged spirochete persistence and infectivity in the mosquito gut. (Which begs the question if this is true for the human gut as well).  Interestingly, in arthropods trypsin increases significantly after blood feeding and plays an important role in early protein degradation.
  • Mechanical transmission experiments revealed no evidence of Borrelia transmission from infected to naive hosts.
  • The study makes the fatal flaw of assuming Ixodes ticks are the SOLE vectors capable of transmitting Lyme disease. There are many other bugs out there that have not been tested for transmission. We also know that human congenital transmission occurs (mother to fetus) and there is much to indicate it can be transmitted sexually as a STD.  It’s important to understand that no studies have ruled out sexual transmission but ‘the powers that be’ continue to proclaim it as fact.

For more:

Others have found various ways Bb is transmitted as well:

Like so many other pioneers who expose inconvenient truths about Lyme, the Michigan State Attorney’s Office told Dr. Mattman to stop testing for Lyme using her gold standard direct culture technique.  She also successfully duplicated the results of the Bowen Q-RiBb test, which provided a preliminary report of the findings within 24 hours of receiving the specimen. The final report included digital photographs of the finding, which was useful in evaluating treatment by comparing pre and post serial dilution results.

Mattman was subsequently threatened with time in jail or a fine of 5,000 dollars a day.  State police arrived at her lab with handcuffs and tried to find evidence that she was still testing but they didn’t find what they were looking for. She was forced to stop her valuable work and leave her lab.

The continued adherence to worthless 2-tier CDC testing is on purpose.  They don’t want an accurate test – they’ve had two already and buried them!

Category:

Lyme, Testing, Ticks, Transmission